Arterial homeostasis, inflammation, and erythropoietic growth factors

Reviews in Cardiovascular Medicine

Volumn 6, Issue SUPPL. 3, 2005, Pages

  Goldschmidt Clermont, Pascal J ^a   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Endothelial progenitor cells; Erythropoietin; Vascular endothelial growth factor

Indexed keywords

ERYTHROPOIETIN; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

AGING; ANGIOGENESIS; ARTERY RECONSTRUCTION; ARTICLE; CELL FUNCTION; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); PREDICTION; PROGNOSIS; RISK FACTOR; SMOKING; STEM CELL; TISSUE INJURY;

ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; GROWTH SUBSTANCES; HEART DISEASES; HOMEOSTASIS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; STEM CELLS;

EID: 28644441734     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;350:1285-1295.
2. McMurray JJV, Pfeffer MA. The year in heart failure. J Am Coll Cardiol. 2004;44:2398-2405.
3. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiological Reviews. 1992;72:449-489.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
5. Goldschmidt-Clermont PJ, Peterson ED. On the memory of a chronic illness. Sci Aging Knowledge Environ (SAGE KE). 2003;45:re8.
6. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
7. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:457-463.
8. Van der Meet P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44:63-67.
9. Jaquet K, Krause K, Tawakol-Khodai, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvascular Research. 2002;64:326-333.
10. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346.
11. Bahlmann FH, de Groot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64:1648-1652.
12. Bahlmann FH, de Groot K, Spandau J-M, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103:921-926.
13. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci. 1995;92:11190-11194.
14. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348:593-600.
15. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Experimental Med. 2005;201:591-601.
16. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by γ interferon can be corrected by recombinant human erythropoietin. Blood. 1991;78:2564-2567.